5 Breast Cancer Clinical Trials in Springdale, AR (2026)

Q: How do I join a clinical trial in Springdale?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Springdale research site will contact you.

Recruiting Breast Cancer Studies in Springdale

NCT06492616Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal G...

Springdale, ARPHASE34,220 participantsStemline Therapeutics, Inc.

View Study Details

NCT07174336Recruiting

A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of LY4064809 to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal gr...

Springdale, ARPHASE3920 participantsEli Lilly and Company

View Study Details

NCT06103864Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemot...

Springdale, ARPHASE3625 participantsAstraZeneca

View Study Details

NCT07173751Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blind...

Springdale, ARPHASE3558 participantsBioNTech SE

View Study Details

NCT06638307Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer....

Springdale, ARPHASE1240 participantsStemline Therapeutics, Inc.

View Study Details

About Breast Cancer Clinical Trials in Springdale

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 5 breast cancer clinical trials recruiting participants in Springdale, AR. These studies are seeking a combined 6,563 participants. Research is being sponsored by Stemline Therapeutics, Inc., Eli Lilly and Company, AstraZeneca and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Springdale — FAQ

Are there breast cancer clinical trials in Springdale?

Yes, there are 5 breast cancer clinical trials currently recruiting in Springdale, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Springdale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Springdale research site will contact you about next steps.

Are clinical trials in Springdale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Springdale studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 5 active trials in Springdale are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 21, 2026 from ClinicalTrials.gov